Sai Parenterals investor presentation: Q2 FY27 revenue jumps on Noumed consolidation as Rs. 571 crore capex builds
Q2 FY27 revenue Rs. 196.1 crore, up 257.4% with Noumed consolidated, but EBITDA margin slipped to 21.1% from 23.3%.
By ScoutQuest · · 1 min read
- Q2 FY27 Revenue
- Rs. 196.1 crore, up 257.4% year on year
- Q2 FY27 EBITDA Margin
- 21.1% against 23.3% a year earlier
- FY27 Guidance
- Rs. 750 crore revenue target with roughly 17% EBITDA margin
- Period
- Q2 & H1 FY27, ended 30 September 2026
- Positioning
- Sai Parenterals presents itself as an oral solids and cephalosporin formulations maker moving into injectables, with acquisition-led reach into regulated ANZ, South-East Asia, Middle East and Latin America markets.
📈 Q2 FY27 consolidated revenue from operations was Rs. 196.1 crore, up 257.4% year on year, with EBITDA of Rs. 41.4 crore and profit after tax of Rs. 10.5 crore. The presentation states the comparison is not like-for-like, because Q2 FY27 includes a full quarter of Noumed Pharmaceuticals, consolidated with effect from 12 November 2025, which the year-earlier period does not.
📈 Margins moved the other way: the presentation shows Q2 FY27 EBITDA margin at 21.1% against 23.3% a year earlier, with the year-on-year comparison again flagged as not like-for-like. Management nevertheless guides to an EBITDA margin of about 17% for FY27 as a whole, bridging up from 14.6% in Q4 FY26.
💰 On a full-year basis, consolidated revenue from operations was Rs. 386.0 crore in FY26 and profit after tax Rs. 14.3 crore, with the deck noting that FY26 is the first year to include Noumed. The presentation frames the coming period as an investment phase, with FY27 described as the peak debt year before deleveraging from FY28.
🏭 Management states FY27 is an execution-focused growth year with a Rs. 750 crore revenue target and roughly 17% EBITDA margin, and that FY28 is the inflection point as the Rs. 571 crore capex programme monetises. It attributes the FY27 target to existing long-term supply contracts, a CDMO export ramp-up and a full year's contribution from Noumed.
Also from Sai Parenterals
Sai Parenterals Ltd press release, Q2 FY27
1 Nov 2026
Consolidated results for the quarter Ended 30.09.2026
1 Nov 2026
Q2 FY27 results, buyout of remaining 25% in SP Analytics, Saicriti Pharma deal completed
1 Nov 2026
More numbers
- Revenue from operations, Q2 FY27196.1 (Rs. in crore)
- Revenue growth year on year, Q2 FY27257.4%
- EBITDA, Q2 FY2741.4 (Rs. in crore)
- Profit after tax, Q2 FY2710.5 (Rs. in crore)
- EBITDA margin, Q2 FY2721.1%
- EBITDA margin, Q2 FY2623.3%
- Revenue from operations, FY26386.0 (Rs. in crore)
- Profit after tax, FY2614.3 (Rs. in crore)
- Revenue target, FY27Rs. 750 crore
- EBITDA margin target, FY27~17%
- Capex programme across four projectsRs. 571 crore
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.